Amrix is a brand name of cyclobenzaprine, approved by the FDA in the following formulation(s):
AMRIX (cyclobenzaprine hydrochloride - capsule, extended release; oral)
Manufacturer: ANESTA AG
Approval date: February 1, 2007
Strength(s): 15MG [AB], 30MG [RLD][AB]
Has a generic version of Amrix been approved?
A generic version of Amrix has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Amrix and have been approved by the FDA:
cyclobenzaprine hydrochloride capsule, extended release; oral
Manufacturer: MYLAN
Approval date: April 18, 2011
Strength(s): 15MG [AB], 30MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Amrix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Modified release dosage forms of skeletal muscle relaxants
Patent 7,387,793
Issued: June 17, 2008
Inventor(s): Venkatesh; Gopi & Clevenger; James M.
Assignee(s): Eurand, Inc.
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Patent expiration dates:
- February 26, 2025
✓
Drug product
Modified release dosage forms of skeletal muscle relaxants
Patent 7,544,372
Issued: June 9, 2009
Inventor(s): Venkatesh; Gopi & Clevenger; James M.
Assignee(s): Eurand, Inc.
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration-time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Patent expiration dates:
Modified release dosage forms of skeletal muscle relaxants
Patent 7,790,199
Issued: September 7, 2010
Inventor(s): Venkatesh; Gopi & Clevenger; James M.
Assignee(s): Eurand, Inc.
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Patent expiration dates:
- November 14, 2023
✓
Drug product
Modified release dosage forms of skeletal muscle relaxants
Patent 7,820,203
Issued: October 26, 2010
Inventor(s): Venkatesh; Gopi & Clevenger; James M.
Assignee(s): Eurand, Inc.
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Patent expiration dates:
- November 14, 2023
✓
Drug product
Modified release dosage forms of skeletal muscle relaxants
Patent 7,829,121
Issued: November 9, 2010
Inventor(s): Venkatesh; Gopi & Clevenger; James M.
Assignee(s): Eurand Inc.
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Patent expiration dates:
See also...
- Amrix Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Amrix Consumer Information (Cerner Multum)
- Amrix Advanced Consumer Information (Micromedex)
- Cyclobenzaprine Consumer Information (Drugs.com)
- Cyclobenzaprine Consumer Information (Wolters Kluwer)
- Cyclobenzaprine Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Cyclobenzaprine Consumer Information (Cerner Multum)
- FusePaq Tabradol Advanced Consumer Information (Micromedex)
- Cyclobenzaprine Advanced Consumer Information (Micromedex)
- Cyclobenzaprine AHFS DI Monographs (ASHP)
